An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers

Abstract

MHC class I antigen presentation deficiency is considered to be the most prevalent cancer immune escape mechanism. Despite its increasing occurrence, the mechanistic implications, and potential strategies to address this challenge, remain poorly understood. Studying {beta}2-microglobulin (B2M) deficient mouse tumor models, we found that MHC class I loss leads to a substantial immune desertification of the tumor microenvironment (TME) and broad therapeutic resistance to immune-, chemo- and radiotherapy. We show that treatment with long-lasting mRNA-encoded interleukin-2 (IL2) restores an immune cell infiltrated, IFN{gamma}-promoted, highly proinflammatory TME signa-ture, and when combined with a tumor-targeting monoclonal antibody (mAb), can overcome ther-apeutic resistance. Surprisingly, we identified that effectiveness of this treatment is driven by ne-oantigen-specific IFN{gamma}-releasing CD8+ T cells that recognize neoantigens cross-presented by TME-resident activated macrophages that under IL2 treatment acquire augmented antigen presen-tation proficiency along with other M1-phenotype-associated features. Our findings highlight the unexpected importance of restoring neoantigen-specific immune responses in the treatment of cancers with MHC class I deficiencies.